Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10485644 | 0.96 | ESR1 (0.36) | ESR1ESR2ALDH1A1L3MBTL1 | |
| SCHEMBL20854324 | 0.74 | ESR1 (0.36) | ESR1ESR2ALDH1A1L3MBTL1 | |
| SCHEMBL2640063 | 0.72 | PGR (0.34) | ESR1ESR2CRBN | |
| SCHEMBL8467345 | 0.69 | ESR1 (0.35) | ESR1ESR2ALDH1A1L3MBTL1 | |
| SCHEMBL22767562 | 0.69 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL6377360 | 0.69 | MAPK1 (0.32) | ALDH1A1 | |
| SCHEMBL2982384 | 0.69 | ALDH1A1 (0.33) | ESR1ESR2ALDH1A1L3MBTL1 | |
| SCHEMBL2015392 | 0.69 | ALDH1A1 (0.35) | ESR1ESR2ALDH1A1L3MBTL1CRBN | |
| SCHEMBL2988042 | 0.69 | ALDH1A1 (0.33) | ESR1ESR2ALDH1A1L3MBTL1 | |
| SCHEMBL2015391 | 0.69 | ALDH1A1 (0.35) | ESR1ESR2ALDH1A1L3MBTL1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-11-23 | — | — | US | disclosed |
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | CXXC5, ZRANB2, GZMB | ESR1 4531/4885ESR2 4224/4885ALDH1A1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.